Nexturastat A
| Code | Size | Price |
|---|
| AG-CR1-3901-M001 | 1 mg | £120.00 |
Quantity:
| AG-CR1-3901-M005 | 5 mg | £450.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
+4°C (short term), -20°C (long term).
Documents
Further Information
Alternate Names/Synonyms:
4-((1-Butyl-3-phenylureido)methyl)-N-hydroxybenzamide
Appearance:
Light pink solid.
CAS:
1403783-31-2
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.
InChi:
InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)
InChiKey:
JZWXMCPARMXZQV-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1403783-31-2. Formula: C19H23N3O3. MW: 341.4. Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50 =5.02nM). Displays high selectivity over all other HDACs (IC50=3-10µM). Suppresses cell proliferation and promotes apoptosis in B16 cells (GI50=14.3µM) and human lymphoma cells HuT-78. Dose-dependently induces hyperacetylation of alpha-tubulin in B16 murine melanoma cells without elevating histone H3 acetylation. Induces cell cycle arrest in G1. HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
MDL:
MFCD28099804
Molecular Formula:
C19H23N3O3
Molecular Weight:
341.4
Package Type:
Vial
Product Description:
Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC50 =5.02nM). Displays high selectivity over all other HDACs (IC50=3-10µM). Suppresses cell proliferation and promotes apoptosis in B16 cells (GI50=14.3µM) and human lymphoma cells HuT-78. Dose-dependently induces hyperacetylation of alpha-tubulin in B16 murine melanoma cells without elevating histone H3 acetylation. Induces cell cycle arrest in G1. HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.
Purity:
>98% (HPLC)
SMILES:
CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC1=CC=CC=C1
Solubility Chemicals:
Soluble in DMSO. Slightly soluble in methanol or ethanol (1mg/ml). Almost insoluble in water.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth: J.A. Bergman, et al.; J. Med. Chem. 55, 9891 (2012) | Development and therapeutic implications of selective histone deacetylase 6 inhibitors: J.H. Kalin & J.A Bergman; J. Med. Chem. 56, 6297 (2013) | Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation: K.V. Woan, et al.; Mol. Oncol. 9, 1447 (2015) | Trend of histone deacetylase inhibitors in cancer therapy: Isoform selectivity or multitargeted strategy: L. Zhang, et al.; Med. Res. Rev. 35, 63 (2015) (Review)
Related Products
| Product Name | Product Code | Supplier | Nexturastat B | AG-CR1-3902 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACY-775 | AG-CR1-3903 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DMAPB | AG-CR1-3904 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PMPH | AG-CR1-3905 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DABPH | AG-CR1-3906 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MBIMPH | AG-CR1-3907 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MBIMPH F-Analog 1 . HCl | AG-CR1-3908 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MBIMPH F-Analog 2 | AG-CR1-3909 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||